History

5-Amino-1MQ comes out of work on small-molecule inhibitors of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in adipose tissue and liver in obesity. The foundational study (Neelakantan et al., Biochemical Pharmacology 2018) reported that a series of cell-permeable methylquinolinium NNMT inhibitors — including 5-amino-1MQ — reversed high-fat-diet-induced obesity in mice, reducing body weight, fat mass, adipocyte size and plasma cholesterol. The 5-amino substitution distinguishes it from the parent compound 1-methylquinolinium (1-MQ) and gives roughly a tenfold gain in potency.

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT that is increasingly marketed online as a “fat-loss peptide.” It is not a peptide, and that mislabeling is the first red flag. The underlying biology is genuinely interesting and the mouse data are encouraging, but the honest summary is simple: as of mid-2026 there is no verifiable human trial, no approval, and every credible efficacy result comes from animals or cell studies. This profile separates the real preclinical science from the grey-market marketing.

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). It is a methylquinolinium chemical, typically supplied as the iodide salt. It is NOT a peptide, and not a SARM or anabolic steroid. It is distinct from the parent compound 1-methylquinolinium (1-MQ); the 5-amino substitution gives roughly a tenfold increase in potency — an IC50 of about 1.2 µM versus about 12 µM for 1-MQ, a figure explicitly confirmed in the NNMT mechanism review (Iyamu & Huang 2021).

Mechanistically, NNMT methylates nicotinamide to 1-methylnicotinamide (1-MNA), consuming S-adenosylmethionine (SAM) as the methyl donor. 5-Amino-1MQ binds the nicotinamide (substrate) site of the enzyme — making it a substrate-site (nicotinamide-competitive) inhibitor rather than a generic “competitive inhibitor.” By blocking NNMT it is proposed to spare SAM/methyl-donor pools and shift nicotinamide back toward NAD+ salvage, with downstream effects on adipocyte energy metabolism. Because NNMT is overexpressed in adipose tissue and liver in obesity, the enzyme is an attractive metabolic target — that is the rationale behind the compound.

One important caveat on selectivity: the foundational paper described the methylquinolinium inhibitors as selective, but the 2021 mechanism review explicitly cautions that this chemical class has limited selectivity and low metabolic stability. So “highly selective” should be read as qualified, not settled.

The claims

Vendors and clinics market 5-amino-1MQ for fat loss and weight reduction, “boosting NAD+,” improving insulin sensitivity and metabolic health, and — increasingly — “muscle preservation,” with a framing that you lose fat without losing lean mass. Some pages also assert that Phase 1 human trials have been “registered in some geographies.” It is widely sold as a “research chemical” or grey-market capsule, and very often mislabeled as a peptide.

What the evidence actually shows

Human evidence: none verifiable. No published human efficacy or safety trial could be confirmed in the peer-reviewed literature, and no genuine ClinicalTrials.gov registration (Phase 1, 2, or 3) could be verified. Vendor claims of “registered Phase 1 trials” provide no verifiable registry ID — treat that as unconfirmed and thin. Any human weight-loss, muscle, or metabolic benefit is unproven.

Animal and preclinical (the actual evidence base):

Foundational discovery — small-molecule NNMT inhibitors (the methylquinolinium series, including 5-amino-1MQ) reversed high-fat-diet obesity in mice: reduced body weight, white adipose mass, adipocyte size and plasma cholesterol; reported as selective. Animal only. (Neelakantan et al., Biochemical Pharmacology 2018.)
Metabolic dysfunction model — “5A1MQ” produced dose-dependent reductions in body-weight/fat-mass gain, improved oral glucose tolerance and insulin sensitivity, and reduced hepatic steatosis in diet-induced obese mice. Animal only. (Babula et al., Diabetes, Obesity and Metabolism 2024.)
Diet + NNMT inhibition / microbiome — NNMT inhibition (5-amino-1MQ) combined with a reduced-calorie/low-fat diet shaped a distinct cecal microbiome in diet-induced obese mice. Animal only. (Dimet-Wiley et al., Scientific Reports 2022.)
Muscle/aging — in aged (22-month) female mice, NNMT inhibition increased grip strength (about 40% in sedentary mice, about 60% combined with exercise, an additive effect) and improved running and muscle function. Animal only. (Dimet-Wiley et al., Scientific Reports 2024.)
Class context — a separate NNMT inhibitor, JBSNF-000088 (not 5-amino-1MQ), reduced weight in diet-induced obese mice (Kannt et al., Scientific Reports 2018). Useful as class proof-of-concept, but not the same compound.

A note on the “muscle preservation” / “fat lost without lean loss” framing: it is partially supported by the aged-mouse muscle-function data, but it is not directly demonstrated as preserved lean mass in the obesity papers — those measured adipose and adipocyte endpoints, not lean-mass preservation. Treat the lean-sparing claim as suggestive, not established.

Legal and regulatory status

FDA: Preclinical/research-grade only. As of mid-2026, 5-amino-1MQ is not FDA-approved for any use, is not a dietary supplement, and is not on the FDA 503A compounding list. It is sold as a “research chemical” / grey-market capsule; human clinic use is off-label and not trial-backed.
Clinical trials: No registered or completed human trial for 5-amino-1MQ could be confirmed in any registry. Claims of “registered Phase 1 trials in some geographies” carry no verifiable registry ID and should be treated as unconfirmed.
Anti-doping (WADA): It is not specifically named on the WADA 2026 Prohibited List (in force 1 January 2026), and there is no confirmable WADA classification or Monitoring-Program listing for it. It is not a GLP-1 agonist (NNMT inhibition is a different mechanism), and it is not a growth factor. For context, the 2026 List places GLP-1 agonists such as semaglutide and tirzepatide on the Monitoring Program — not prohibited (a circulating online claim that they were “moved to S4 prohibition” is unsupported by primary WADA documentation). For athletes, an unlisted investigational metabolic agent can still create issues under broad catch-all provisions and is contamination-prone as a grey-market product — clear anything with your anti-doping authority. The precise WADA category is unsettled, not confirmed.

Safety

No human safety data exist. Safety rests entirely on rodent studies, where tolerability at tested doses was reportedly acceptable — no reported mortality or overt organ toxicity in the published mouse work, and the 2024 metabolic-disease paper reported improved liver endpoints and reduced steatosis in treated obese mice.
Anecdotal human “side effects” are not evidence. Marketing and clinic reports of mild GI upset or anecdotal thyroid-marker shifts are uncontrolled, lack baselines, and cannot establish causation. That is anecdote, not data.
Real unknowns: the long-term consequences of chronically altering NAD+/methyl-donor (SAM) balance; off-target effects (the chemical class has documented selectivity and metabolic-stability limits); and the product-quality and purity risk inherent to grey-market “research chemical” material. Bottom line: unapproved, with human safety unestablished.

Bottom line

5-Amino-1MQ is a small-molecule NNMT inhibitor — not a peptide — with a legitimately interesting mechanism and encouraging mouse data across obesity, metabolic dysfunction and muscle aging. But the gap between that and the marketing is large: there is no verifiable human trial, no approval, no confirmable trial registration, and no human safety data. The “muscle-sparing fat loss” pitch is partly extrapolated from aged-mouse muscle studies, not shown as lean-mass preservation in the obesity work. It is a research-grade, grey-market chemical that is frequently and incorrectly sold as a peptide.

A sourcing caution: many consumer pages mislabel this as a “peptide,” and some cite a fabricated PubMed ID (29183836) for the foundational study — that PMID actually points to an unrelated 2018 vinpocetine review (Zhang et al., Eur J Pharmacol) and should be ignored. The correct foundational PMID is 29155147. Verify any citation before relying on it.

Evidence grade: Animal only.